<DOC>
	<DOCNO>NCT00441844</DOCNO>
	<brief_summary>Type I diabetes ( T1DM ) associate increase risk vascular complication . While precise mechanism ( ) diabetes accelerates atherosclerosis elucidate , several line evidence point role increase inflammation pathogenesis vasculopathies . The monocyte-macrophage pivotal cell atherogenesis readily accessible study . However , scanty data monocyte function inflammation T1DM . Simvastatin , HMG-CoA reductase inhibitor , recently show reduce cardiovascular event diabetic patient ( T1DM T2DM Heart Protection Study ) . Recent study demonstrate simvastatin decrease C-reactive protein decrease pro-atherogenic activity monocytes non-diabetic subject . However , paucity data effect simvastatin inflammation monocyte function Type 1 diabetes . Thus , purpose study Aim 1 ) ass biomarkers inflammation T1DM compare match control ( n=50/group ) . Aim 2 ) Also , assess effect simvastatin ( 20mg/day ) therapy inflammation monocyte function T1DM randomize , placebo-controlled , double blind trial .</brief_summary>
	<brief_title>Monocyte Function Inflammation Type 1 Diabetes Its Modulation</brief_title>
	<detailed_description>Type I diabetes ( T1DM ) associate increase risk vascular complication . While precise mechanism ( ) diabetes accelerates atherosclerosis elucidate , several line evidence point role increase inflammation pathogenesis vasculopathies . The monocyte-macrophage pivotal cell atherogenesis readily accessible study . However , scanty data monocyte function inflammation T1DM . Simvastatin , HMG-CoA reductase inhibitor , recently show reduce cardiovascular event diabetic patient ( T1DM T2DM Heart Protection Study ) . Recent study demonstrate simvastatin decrease C-reactive protein decrease pro-atherogenic activity monocytes non-diabetic subject . However , paucity data effect simvastatin inflammation monocyte function Type 1 diabetes . Thus , purpose study Aim 1 ) ass biomarkers inflammation T1DM compare match control ( n=50/group ) . Aim 2 ) Also , assess effect simvastatin ( 20mg/day ) therapy inflammation monocyte function T1DM randomize , placebo-controlled , double blind trial . At baseline post-therapy , fast blood obtain routine laboratory ( include lipid profile , glucose , glycated hemoglobin ) , free fatty acid level , biomarkers inflammation [ high sensitive C-reactive protein , plasma soluble cell adhesion molecule ( sVCAM , sICAM , sE-selectin sP-selectin ) , CD40 ligand , monocyte pro-atherogenic activity ( superoxide anion , monocyte chemotactic protein-1 , interleukin ( IL ) -1b , IL-6 tumor necrosis factor-a release , adhesion human aortic endothelium , CD40 expression ) ] etc. , 24-hour urine microalbumin</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Type I diabetic patient ( onset &lt; 20years insulin therapy since diagnosis ) without clinical macrovascular complication , present age &gt; 20 year duration diabetes &gt; 1yr . HbA1c last year &gt; 10 % Patients glucophage and/or thiazolidenediones exclude , since drug appear antiinflammatory . Theumatoid arthritis ; Abnormal liver function , Hypo hyperthyroidism ; Malabsorption ; Steroid therapy , Antiinflammatory drug except aspirin ( 81mg/day ) Pregnancy , Lactation , Smoking , Abnormal complete blood count ; Alcohol consumption &gt; 1 oz/day</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>diabetes , statin , monocyte , crp , inflammation</keyword>
</DOC>